About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 624 record(s)
Req # A-2022-001233
All records between September 20, 2020 to December 31, 2020 which make any reference to the changes that were made to the noted webpage. https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting/vaccine/consumer.htmlOrganization: Health Canada
November 2023
Req # A-2022-001514
Health Canada has recently signed an agreement with British Columbia (BC) for health data sharing. Provide copy of agreement signed between Feb 1, 2023 and March 2, 2023 between Health Canada and the province of BC. Provide the agreement definition of what ‘‘depersonalized‘‘ health data means. Provide all data points or fields of health information that will be shared between the province of BC and Health Canada under this agreement.Organization: Health Canada
November 2023
Req # A-2023-000016
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Doxorubicin. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Doxorubicin which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24. The strength (s) and dosage form of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Doxorubicin.Organization: Health Canada
November 2023
Req # A-2023-000085
All individual reports with an outcome of death submitted by provincial health ministries, hospitals, product manufacturers or any other party, that are causally, indeterminately, inconsistently, unclassifiably or temporally associated with receipt of any COVID-19 vaccine. Dates: 1 Mar 2020 - April 20, 2023.Organization: Health Canada
November 2023
Req # A-2023-000149
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Enzalutamide; The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Enzalutamide; The strength (s) and dosage form of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 having the medicinal ingredient Enzalutamide.; The Canadian Reference product used to support of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 having the medicinal ingredient Enzalutamide.; Any information pertaining to a Risk Management Plan (RMP) submitted to support of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 having the medicinal ingredient Enzalutamide.Organization: Health Canada
November 2023
Req # A-2023-000445
All records pertaining to the priority review request and decision of lecanemab submitted by Biogen Inc. and Eisai Co., Ltd. to Health Canada. Time period: January 2022 to June 28, 2023.Organization: Health Canada
November 2023
Req # A-2023-000518
All documents, from January 1, 2023, respecting the House of Commons committee consideration of contracts awarded to McKinsey & Company.Organization: Health Canada
November 2023
Req # A-2023-000580
Obtain the briefing file(s) to be provided to Mark Holland, Canada's new Minister of Health, as soon as he takes the position today, July 26, 2023.Organization: Health Canada
November 2023
Req # A-2023-000595
Any briefing materials prepared for the new minister of mental health and addictions who was sworn in on July 26, 2023.Organization: Health Canada
November 2023
Req # A-2023-000643
Briefing booklet/notes provided to incoming minister of health Mark Holland ahead of his July 26, 2023 appointment to the role.Organization: Health Canada
November 2023